Gapping up
In reaction to strong earnings/guidance: N/A.
M&A news: TSL +9% (receives preliminary non-binding proposal to be acquired by CEO and Shanghai Xingsheng Equity Investment & Management for $11.60 per ADS), ATML +5.2% (receives unsolicited proposal to be acquired $9.00 per share), JAH +4.9% (to be acquired by Newell Rubbermaid (NWL) for $60.00/share), MU +1.5% (acquires remaining interest in Inotera Memories of Taiwan; expected to be immediately accretive to EPS)
Select generic pharma names showing strength: MYL +1.4%, PRGO +0.9%, TEVA +0.3%
Other news: IMNP +53% (reports new data regarding tetravalent IgG1-like bi-specific antibodies), BPMX +10.2% (may be related to upcoming investor presentation), CBLI +6.2% (announces the publication of a study in Oncotarget demonstrating the ability of entolimod to suppress liver metastases in a preclinical model of uveal melanoma), MNGA +4.4% (cont strength), UDF +3.6% (issues supplemental statement responding to apparent 'short and distort' attack), BLRX +3.1% (files a regulatory submission to commence a Phase 2 trial for BL-8040 for mobilization and collection of bone marrow stem cells), CTIC +2.7% (receives $10 mln milestone payment for TRISENOX from Teva (TEVA)), JKS +1.7% (TSL peer)
Analyst comments: PBYI +2.6% (upgraded to Buy from Neutral at Citigroup), MAT +2% (upgraded to Outperform from Market Perform at BMO Capital)
In reaction to strong earnings/guidance: N/A.
M&A news: TSL +9% (receives preliminary non-binding proposal to be acquired by CEO and Shanghai Xingsheng Equity Investment & Management for $11.60 per ADS), ATML +5.2% (receives unsolicited proposal to be acquired $9.00 per share), JAH +4.9% (to be acquired by Newell Rubbermaid (NWL) for $60.00/share), MU +1.5% (acquires remaining interest in Inotera Memories of Taiwan; expected to be immediately accretive to EPS)
Select generic pharma names showing strength: MYL +1.4%, PRGO +0.9%, TEVA +0.3%
Other news: IMNP +53% (reports new data regarding tetravalent IgG1-like bi-specific antibodies), BPMX +10.2% (may be related to upcoming investor presentation), CBLI +6.2% (announces the publication of a study in Oncotarget demonstrating the ability of entolimod to suppress liver metastases in a preclinical model of uveal melanoma), MNGA +4.4% (cont strength), UDF +3.6% (issues supplemental statement responding to apparent 'short and distort' attack), BLRX +3.1% (files a regulatory submission to commence a Phase 2 trial for BL-8040 for mobilization and collection of bone marrow stem cells), CTIC +2.7% (receives $10 mln milestone payment for TRISENOX from Teva (TEVA)), JKS +1.7% (TSL peer)
Analyst comments: PBYI +2.6% (upgraded to Buy from Neutral at Citigroup), MAT +2% (upgraded to Outperform from Market Perform at BMO Capital)